Are EPB41 and alpha-synuclein diagnostic biomarkers of sport-related concussion? Findings from the NCAA and Department of Defense CARE Consortium.
Biomarkers
College athletes
Concussion
Mild traumatic brain injury
Sport injury
Journal
Journal of sport and health science
ISSN: 2213-2961
Titre abrégé: J Sport Health Sci
Pays: China
ID NLM: 101606001
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
12
02
2022
revised:
15
07
2022
accepted:
08
10
2022
medline:
17
5
2023
pubmed:
21
11
2022
entrez:
20
11
2022
Statut:
ppublish
Résumé
Current protein biomarkers are only moderately predictive at identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion. This was a multicenter, prospective, case-control study of athletes who provided blood samples and were diagnosed with a concussion or were a matched non-concussed control within the National Collegiate Athletic Association-Department of Defense Concussion Assessment, Research, and Education Consortium conducted between 2015 and 2019. The blood was collected within 48 h of injury to identify protein abnormalities at the acute and subacute timepoints. Athletes with concussion were divided into 6 h post-injury (0-6 h post-injury) and after 6 h post-injury (7-48 h post-injury) groups. We applied a highly multiplexed proteomic technique that used a DNA aptamers assay to target 1305 proteins in plasma samples from athletes with and without sport-related concussion. A total of 140 athletes with concussion (79.3% males; aged 18.71 ± 1.10 years, mean ± SD) and 21 non-concussed athletes (76.2% males; 19.14 ± 1.10 years) were included in this study. We identified 338 plasma proteins that significantly differed in abundance (319 upregulated and 19 downregulated) in concussed athletes compared to non-concussed athletes. The top 20 most differentially abundant proteins discriminated concussed athletes from non-concussed athletes with an area under the curve (AUC) of 0.954 (95% confidence interval: 0.922‒0.986). Specifically, after 6 h of injury, the individual AUC of plasma erythrocyte membrane protein band 4.1 (EPB41) and alpha-synuclein (SNCA) were 0.956 and 0.875, respectively. The combination of EPB41 and SNCA provided the best AUC (1.000), which suggests this combination of candidate plasma biomarkers is the best for diagnosing concussion in athletes after 6 h of injury. Our data suggest that proteomic profiling may provide novel diagnostic protein markers and that a combination of EPB41 and SNCA is the most predictive biomarker of concussion after 6 h of injury.
Sections du résumé
BACKGROUND
Current protein biomarkers are only moderately predictive at identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion.
METHODS
This was a multicenter, prospective, case-control study of athletes who provided blood samples and were diagnosed with a concussion or were a matched non-concussed control within the National Collegiate Athletic Association-Department of Defense Concussion Assessment, Research, and Education Consortium conducted between 2015 and 2019. The blood was collected within 48 h of injury to identify protein abnormalities at the acute and subacute timepoints. Athletes with concussion were divided into 6 h post-injury (0-6 h post-injury) and after 6 h post-injury (7-48 h post-injury) groups. We applied a highly multiplexed proteomic technique that used a DNA aptamers assay to target 1305 proteins in plasma samples from athletes with and without sport-related concussion.
RESULTS
A total of 140 athletes with concussion (79.3% males; aged 18.71 ± 1.10 years, mean ± SD) and 21 non-concussed athletes (76.2% males; 19.14 ± 1.10 years) were included in this study. We identified 338 plasma proteins that significantly differed in abundance (319 upregulated and 19 downregulated) in concussed athletes compared to non-concussed athletes. The top 20 most differentially abundant proteins discriminated concussed athletes from non-concussed athletes with an area under the curve (AUC) of 0.954 (95% confidence interval: 0.922‒0.986). Specifically, after 6 h of injury, the individual AUC of plasma erythrocyte membrane protein band 4.1 (EPB41) and alpha-synuclein (SNCA) were 0.956 and 0.875, respectively. The combination of EPB41 and SNCA provided the best AUC (1.000), which suggests this combination of candidate plasma biomarkers is the best for diagnosing concussion in athletes after 6 h of injury.
CONCLUSION
Our data suggest that proteomic profiling may provide novel diagnostic protein markers and that a combination of EPB41 and SNCA is the most predictive biomarker of concussion after 6 h of injury.
Identifiants
pubmed: 36403906
pii: S2095-2546(22)00114-4
doi: 10.1016/j.jshs.2022.11.007
pmc: PMC10199139
pii:
doi:
Substances chimiques
erythrocyte membrane band 4.1 protein
0
alpha-Synuclein
0
Biomarkers
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-387Informations de copyright
Copyright © 2023. Production and hosting by Elsevier B.V.
Références
Cardiovasc Res. 2017 Dec 1;113(14):1708-1718
pubmed: 29016754
JAMA Netw Open. 2020 Jan 3;3(1):e1919771
pubmed: 31977061
J Cell Physiol. 2015 May;230(5):1024-32
pubmed: 25251017
Ann Neurol. 2017 Nov;82(5):795-812
pubmed: 29059494
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
Soc Sci Med. 2015 Jun;134:66-75
pubmed: 25917137
Neurology. 2012 May 1;78(18):1428-33
pubmed: 22517109
J Neurotrauma. 2017 Mar 1;34(5):1124-1127
pubmed: 27539721
Curr Biol. 1998 Nov 19;8(23):1269-72
pubmed: 9822582
Neurology. 2018 Oct 9;91(15):e1385-e1389
pubmed: 30209234
Neurosurgery. 2014 Sep;75 Suppl 1:S3-15
pubmed: 25006974
Anesthesiology. 2004 Dec;101(6):1262-8
pubmed: 15564931
J Open Res Softw. 2017;5:
pubmed: 29951204
Physiol Rev. 2018 Oct 1;98(4):2381-2430
pubmed: 30156493
Neurology. 2018 May 15;90(20):925-930
pubmed: 29653988
JAMA Netw Open. 2021 Feb 1;4(2):e2037731
pubmed: 33616662
J Athl Train. 2021 Feb 1;56(2):157-163
pubmed: 33596598
Tohoku J Exp Med. 2008 Mar;214(3):213-20
pubmed: 18323691
Br J Anaesth. 2018 Jun;120(6):1158-1164
pubmed: 29793582
J Clin Invest. 1999 Feb;103(3):331-40
pubmed: 9927493
Alzheimers Dement. 2019 Nov;15(11):1478-1488
pubmed: 31495601
Circulation. 2018 Mar 20;137(12):1270-1277
pubmed: 29222138
J Biol Chem. 2014 Jul 4;289(27):18957-65
pubmed: 24855640
Neurology. 2013 Apr 30;80(18):1662-8
pubmed: 23553480
Am J Clin Pathol. 2010 Jul;134(1):157-62
pubmed: 20551280
Ann Neurol. 2020 Jun;87(6):907-920
pubmed: 32215965
Sports Med. 2017 Jul;47(7):1437-1451
pubmed: 28281095
J Trauma. 2005 Nov;59(5):1086-91
pubmed: 16385284
Cell. 2013 Jul 18;154(2):391-402
pubmed: 23870127
Nat Rev Neurosci. 2001 Jul;2(7):492-501
pubmed: 11433374
Circulation. 2005 Nov 1;112(18):2851-6
pubmed: 16267258
Br J Sports Med. 2017 Jun;51(12):969-977
pubmed: 28455362
J Head Trauma Rehabil. 2006 Sep-Oct;21(5):375-8
pubmed: 16983222
Biochim Biophys Acta. 2014 Feb;1838(2):605-19
pubmed: 23747363
Nat Rev Neurol. 2013 Apr;9(4):201-10
pubmed: 23399646
Adv Exp Med Biol. 2013;735:283-300
pubmed: 23402035
Lancet Neurol. 2018 Sep;17(9):782-789
pubmed: 30054151
Brain Res Bull. 2017 Jul;133:60-70
pubmed: 27993598
Neurology. 2020 Sep 1;95(9):e1267-e1284
pubmed: 32747521